Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial

Fig. 5

HbA1c: The strongest effect of all the variable is the effect on time on HbA1c (p < 0.005), which means HbA1c went down substantially in both the treatment and control group. Even though the effect of treatment on this variable was not significant after the effect of time was accounted for, interesting trend pattern can be appreciated when it’s graphed. The Hba1c is relatively stable in the placebo group but has a clear downward trend in the treatment group

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840